Endocrinology Research Analysis
Endocrinology in 2025-Q4 coalesced around actionable cardio-renal-metabolic therapeutics and mechanistic blueprints for disease modification. First-in-class clinical advances included an aldosterone synthase inhibitor (baxdrostat) achieving meaningful blood pressure reductions in resistant hypertension and an APOC3 antisense therapy (olezarsen) reducing acute pancreatitis in severe hypertriglyceridemia. Translational nephrology progressed via a microbiota-derived peptide (corisin) with antibody